Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?

Over the trailing 12 months through Oct. 15, 2026, the iShares U.S. Pharmaceuticals ETF (IHE) returned 38.2%, outperforming VanEck Pharmaceutical ETF (PPH) at 26.4%; IHE also had a shallower five-year maximum drawdown (16.0% vs. 20.3%). PPH had the slightly lower expense ratio (0.36% vs. 0.37%) and higher trailing-12-month yield (1.9% vs. 1.4%), while offering broader international exposure. The article links IHE’s recent performance to its 25.24% Eli Lilly holding and the strength of Lilly’s GLP-1 drugs, and presents the funds as serving different investor preferences.

Analysis

The key portfolio distinction is not “U.S. versus global” so much as differing single-name and product-cycle exposure. Both funds remain materially exposed to Lilly, so PPH is not a clean hedge against a reversal in GLP-1 expectations; IHE’s larger Lilly weight makes it more sensitive to Lilly-specific execution, reimbursement and competitive news. PPH’s additional non-U.S. holdings diversify company and currency exposure, but do not eliminate sector-wide drug-pricing, patent-expiry or regulatory risks. The trailing performance gap is backward-looking and should not be extrapolated as evidence of persistent earnings outperformance. Likewise, PPH’s higher trailing distribution is not a forward income commitment.

Over days, Lilly trial, supply, reimbursement or guidance updates are likely to dominate relative ETF moves. Over 1–3 months, compare revisions to underlying companies’ sales/guidance and changes in Lilly’s weight-driven contribution—not just ETF returns. Over 6–18 months, product-cycle breadth and patent or pricing pressure matter more than geographic labels. The contrarian case is that investors may be buying IHE after a strong run for a concentrated GLP-1 exposure, while assuming PPH is broadly diversified despite meaningful top-holding concentration. No compelling directional ETF trade follows from trailing returns alone; verify current holdings, valuations and earnings revisions before acting.

Key Decisions for Investors

• Do not chase IHE solely on its trailing outperformance. If adding pharma exposure, size it as a concentrated active bet and review Lilly’s current weight and earnings-revision contribution first.
• For a relative-value expression, consider a small dollar-neutral long PPH/short IHE only if the thesis is that Lilly-led U.S. leadership will cool while non-U.S. holdings hold up. This is not a pure geography hedge; monitor Lilly exposure, currency moves and constituent revisions. Falsify the thesis if Lilly guidance and earnings revisions continue to broaden upward relative to PPH’s other major holdings.
• Treat PPH’s higher trailing yield as historical, not forecast income. Verify distribution composition and current holdings before using it as an income allocation.
• Near-term alerts: Lilly guidance, obesity-drug reimbursement or regulatory changes, and material patent/pricing developments across large pharma. Reassess if those signals produce sustained relative earnings-revision divergence; otherwise, no trade is warranted from the supplied comparison alone.